10-Q: Karyopharm Faces Going Concern Doubt Amid Q2 Loss

Karyopharm Therapeutics reported a significant net loss in Q2 2025 and disclosed substantial doubt about its ability to continue as a going concern, prompting a review of strategic alternatives.

Summary

• Reported a net loss of $60.7 million for the six months ended June 30, 2025, a significant increase from $13.6 million in the same period last year.
• Product revenue decreased by 6% to $50.7 million for the six months ended June 30, 2025, compared to $54.0 million in the prior year period, primarily due to increased product return reserves.
• License and other revenue decreased by 21% to $17.2 million for the six months ended June 30, 2025, down from $21.9 million, largely due to a non-recurring license revenue in 2024.
• Operating expenses decreased by 9% to $125.6 million for the six months ended June 30, 2025, driven by cost reduction initiatives and reduced scope in the multiple myeloma trial.
• Cash, cash equivalents, and investments totaled $51.7 million as of June 30, 2025.
• Management concluded there is substantial doubt about the company's ability to continue as a going concern within one year, citing debt obligations and minimum liquidity covenants.
• Current cash resources are expected to fund operations and debt obligations only into October 2025.
• A 1-for-15 reverse stock split was effected on February 25, 2025, to regain Nasdaq compliance.
• The Board is evaluating potential financing transactions and strategic alternatives, including a merger or sale of the company.
• Workforce was reduced by approximately 20% on July 11, 2025, as part of cost management.

Sentiment

Score: 2

Explanation: The company faces severe liquidity challenges, with substantial doubt about its ability to continue as a going concern and a very short cash runway. While cost-cutting measures are in place and some product revenue growth was seen in Q2, overall revenue declined, and net losses significantly widened. The need for immediate capital raises or strategic alternatives, including a potential sale or liquidation, indicates a highly precarious financial position.

Positives

• Net cash used in operating activities decreased by $24.5 million for the six months ended June 30, 2025, compared to the same period in 2024, primarily due to cost reduction initiatives.
• Product revenue for the three months ended June 30, 2025, increased by $1.6 million (6%) compared to the prior year quarter, driven by gross-to-net favorability from lower 340B discounts.
• The company expects net product revenue to increase in the second half of 2025 due to lower product returns, lower 340B discounts, and increased demand.
• Research and development expenses decreased by $6.4 million (9%) for the six months ended June 30, 2025, reflecting cost reduction initiatives and reduced scope of the Phase 3 multiple myeloma trial.
• Selling, general and administrative expenses decreased by $4.8 million (8%) for the six months ended June 30, 2025, due to headcount reductions.
• Regained compliance with Nasdaq's minimum bid price rule on March 13, 2025.

Negatives

• Reported a net loss of $60.7 million for the six months ended June 30, 2025, a significant increase from a $13.6 million loss in the prior year period.
• Total revenue decreased by $7.9 million (10%) to $67.9 million for the six months ended June 30, 2025, compared to $75.9 million in the prior year.
• Cash, cash equivalents, and investments decreased to $51.7 million as of June 30, 2025, from $62.5 million cash and cash equivalents and $46.2 million investments as of December 31, 2024.
• Substantial doubt exists regarding the company's ability to continue as a going concern within one year.
• Current cash resources are expected to fund operations and debt obligations only into October 2025, primarily due to the $24.5 million 2025 Notes maturity and a $25.0 million minimum liquidity covenant.
• The company's accumulated deficit reached $1.6 billion as of June 30, 2025.
• License and other revenue is expected to decrease in the second half of 2025 due to a limitation on Menarini development expense reimbursements ($1.5 million for H2 2025).
• Delays in the Phase 3 endometrial cancer trial (EC-042 Trial) due to higher than expected screen failure rates and ongoing discussions with the FDA regarding the evolving treatment landscape.
• Significant decrease in net cash provided by financing activities ($40.6 million decrease) for the six months ended June 30, 2025, compared to the prior year, which included proceeds from a term loan.
• The company's indebtedness of $356.7 million could limit cash flow and expose it to risks.
• The 2025 Notes, with an aggregate principal amount of $24.5 million, mature on October 15, 2025, and the company does not expect holders to convert them given the current stock price.
• The potential for dissolution and liquidation if financing or strategic alternatives are unsuccessful, which could result in a total loss of investment for stockholders.

Risks

• Financial condition raises substantial doubt about the ability to continue as a going concern.
• Incurred significant losses since inception and expects to continue incurring significant losses, may never achieve or maintain profitability.
• Need additional funding or strategic alternatives to achieve business objectives; inability to raise sufficient capital or enter into strategic alternatives on acceptable terms may force delays, reductions, or elimination of R&D programs and/or commercialization efforts.
• Evaluation of strategic alternatives (merger, sale, restructurings, debt refinancings) is uncertain and may not be successful, potentially leading to dissolution and liquidation with total loss for stockholders.
• Amended Revenue Interest Agreement with KKR contains covenants that, if violated, could accelerate payments or lead to foreclosure on pledged collateral.
• Credit Agreement and 2029 Notes indenture contain covenants (including minimum $25.0 million liquidity) that, if violated, could accelerate payments or lead to foreclosure on pledged collateral.
• Indebtedness ($356.7 million as of June 30, 2025) could limit cash flow, expose to risks, and impair ability to satisfy obligations.
• Raising additional capital and other equity issuances may cause dilution to stockholders, restrict operations, or require relinquishing rights to product candidates.
• Unstable market and economic conditions (tariffs, trade restrictions, conflicts, inflation, high interest rates, banking system instability) may adversely affect business, financial condition, and stock price.
• Business is substantially dependent on the commercial success of XPOVIO; failure to successfully commercialize current and future indications would materially harm the business.
• Substantial competition in the cancer field from companies with greater resources, potentially leading to more effective, safer, or cheaper competing drugs.
• Clinical development is lengthy, expensive, and uncertain; inability to successfully enroll patients or failure to demonstrate safety and effectiveness could incur additional costs, delay approvals, or prevent commercialization.
• Results of previous clinical trials may not be predictive of future trial results; interim/top-line data are subject to change.
• May not be successful in identifying or discovering additional potential product candidates, or prioritization decisions may prove wrong.
• Inability to maintain or expand sales, marketing, and distribution capabilities could hinder commercialization success.
• Products may not receive coverage or may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Product liability lawsuits could divert resources, incur substantial liabilities, and limit commercialization.
• Business conducted outside the U.S. may be adversely affected by international risks and uncertainties (intellectual property protection, regulatory requirements, economic weakness, geopolitical conflicts, FCPA).
• Regulatory approval process is expensive, time-consuming, and uncertain; may not receive approvals in a timely manner or at all.
• May seek accelerated development pathways (Breakthrough Therapy, Fast Track, Priority Review, PRIME) but may not receive them, or they may not lead to faster development/approval.
• May not obtain orphan drug exclusivity, or exclusivity may not prevent competing products.
• Current and future legislation (e.g., IRA, state drug price transparency laws) may increase difficulty and cost of obtaining marketing approval and commercialization, and affect prices.
• Relationships with healthcare providers, physicians, and third-party payers are subject to anti-kickback, fraud and abuse, and other healthcare laws, exposing the company to sanctions.
• Reporting and payment obligations under Medicaid Drug Rebate Program and other governmental drug pricing programs are complex; non-compliance could lead to penalties.
• Subject to stringent privacy laws, information security laws, regulations, policies, and contractual obligations related to data privacy and security; failure to comply could lead to fines and penalties.
• Employees, independent contractors, consultants, collaborators, and vendors may engage in misconduct or improper activities, causing significant liability.
• Failure to comply with environmental, health, and safety laws could lead to fines or penalties.
• Laws governing international operations may preclude development/manufacturing/selling certain products outside the U.S. and require costly compliance programs.
• CREATES Act exposes the company to litigation and damages by competitors claiming insufficient quantities of products for generic/biosimilar testing.
• Governmental export and import controls could impair ability to compete internationally.
• Changes in and uncertainty surrounding U.S. trade policy (tariffs, trade restrictions, BIOSECURE Act) could impact business.
• Biopharmaceutical industry is subject to extensive regulatory obligations and policies that may change due to judicial challenges, election cycles, etc.
• Dependence on third parties for manufacturing; difficulties, disruptions, delays, or unexpected costs could adversely affect results.
• Reliance on third parties for clinical trials and research; unsatisfactory performance could delay or impair regulatory approval.
• Reliance on third parties for investigator-sponsored clinical trials; failure to meet obligations could delay or impair regulatory approval.
• Inability to obtain and maintain patent protection or if scope is not broad enough, competitors could commercialize similar drugs.
• Involvement in lawsuits to protect or enforce intellectual property rights could be expensive, time-consuming, and unsuccessful.
• Third parties may allege infringement of their intellectual property rights, leading to uncertain outcomes and material adverse effects.
• Claims that employees wrongfully used or disclosed trade secrets of former employers.
• Intellectual property litigation could cause substantial resource expenditure and distract personnel.
• Failure to comply with governmental patent agency requirements could reduce or eliminate patent protection.
• If product candidates obtain regulatory approval, additional competitors could enter with generic versions, leading to material decline in sales.
• Failure to successfully extend patent terms under Hatch-Waxman Amendments could harm business.
• Inability to protect confidentiality of trade secrets would harm business and competitive position.
• Not all trademarks are registered; failure to secure registrations could adversely affect business.
• Future success depends on ability to retain key management and attract/retain qualified personnel; workforce reductions may decrease morale and increase turnover.
• Business and operations may be adversely affected by IT system failures or security breaches; costs of data protection measures could be significant.
• Failure to maintain compliance with Nasdaq listing requirements could lead to delisting.
• Substantial number of warrants outstanding; exercise will dilute existing stockholders and could adversely affect trading price.
• Liquidity of common stock may be adversely affected by reverse stock split.
• Provisions in corporate charter documents and Delaware law could make acquisition more difficult and prevent attempts to replace management.
• Price of common stock has been and may continue to be volatile.
• Securities or other litigation could result in substantial costs and divert management time and attention from the business.
• Broad discretion in the use of cash, cash equivalents, and investments; may not use them effectively.
• As a smaller reporting company, reduced disclosure requirements may make common stock less attractive.
• Material weakness in internal control over financial reporting could adversely affect business and financial results.
• Inaccurate estimates or assumptions in financial statements, guidance, or market opportunities may cause actual results to vary.
• Ability to use net operating loss carryforwards and tax credit carryforwards may be limited.
• Changes in tax laws or in their implementation or interpretation may adversely affect business and financial condition.

Future Outlook

The company expects net product revenue to increase in the second half of 2025 compared to the first half, driven by lower product returns, reduced 340B discounts, and increased demand. However, license and other revenue is projected to decrease in the second half of 2025 due to limited reimbursement for development-related expenses from Menarini. Research and development and selling, general and administrative expenses are anticipated to remain relatively consistent in the second half of 2025, with continued investment in myelofibrosis and endometrial cancer Phase 3 trials, offset by ongoing cost reduction initiatives and fees related to strategic alternatives. The company's current cash, cash equivalents, and investments are expected to fund operations and debt obligations only into October 2025, necessitating additional funding or strategic alternatives to continue as a going concern.

Management Comments

• Our continued operations are dependent on our ability to raise additional funding or enter in other strategic alternatives and marketing XPOVIO in its currently approved indications.
• Based on our current business plan and current capital resources, given the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations... we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.
• We plan to address the conditions that raise substantial doubt regarding our ability to continue as a going concern by, among other things, obtaining additional funding through equity offerings, debt financings and refinancings, collaborations, strategic alliances and/or licensing arrangements.
• As we announced on July 11, 2025, our Board is evaluating potential financing transactions, along with strategic alternatives, which may include a potential merger or sale of the Company; in or out of court restructurings; repurchases, redemptions, exchanges or other refinancings of our existing debt; among other potential alternatives.
• As we announced on July 11, 2025, we reduced our workforce by approximately 20 % as part of our ongoing careful management of operating expenses.
• In August 2025, we announced that we expect to close new patient screening in our Phase 3 myelofibrosis trial in August 2025 and expect to report top-line data from this trial in March 2026.
• We expect net product revenue to increase in the second half of 2025 as compared to the first half of 2025 due to gross-to-net favorability, driven by lower product returns and lower 340B discounts than the first half of the year, coupled with increased demand.
• We expect license and other revenue to decrease in the second half of 2025 as compared to the first half of 2025 primarily because the reimbursement of development-related expenses from Menarini is limited to $1.5 million for the second half of 2025.
• We expect our research and development expenses to be relatively consistent in the second half of 2025 as compared to the first half of 2025 as we continue to invest in our myelofibrosis and endometrial cancer Phase 3 clinical trials.
• We expect our selling, general and administrative expenses to remain relatively consistent in the second half of 2025 as compared to the first half of 2025 due to our ongoing cost reduction initiatives, offset by fees to be incurred in connection with pursuit of strategic alternatives, such as efforts to extend our cash runway.

Industry Context

The biopharmaceutical industry, particularly oncology, is highly competitive with new therapies constantly emerging. Karyopharm's lead asset, XPOVIO, faces competition from recently approved novel therapeutics in multiple myeloma, such as bispecific T-cell engagers (TECVAYLI, ELREXFIO, TALVEY) and CAR T-cell therapies (CARVYKTI, Abecma), which are expanding into earlier lines of treatment. The company's focus on SINE compounds represents a novel mechanism of action, but its financial challenges and need for additional funding highlight the capital-intensive nature of drug development and commercialization in this sector. Regulatory changes, such as the FDA's Project Optimus and the EU's Clinical Trials Regulation, are also shaping the development landscape, requiring adaptive strategies for clinical trials and approvals.

Comparison to Industry Standards

• The company's accumulated deficit of $1.6 billion and recurring losses are common for commercial-stage pharmaceutical companies heavily investing in R&D, but the 'substantial doubt about going concern' indicates a more severe liquidity challenge compared to peers with stronger cash positions or clearer paths to profitability.
• The competitive landscape in multiple myeloma, with new approvals like TECVAYLI, ELREXFIO, TALVEY, CARVYKTI, and Abecma, suggests that Karyopharm's XPOVIO faces intense competition from innovative therapies, potentially impacting its market share and revenue growth compared to companies with broader or more differentiated pipelines.
• The company's reliance on third-party manufacturers and CROs is standard industry practice, but any disruptions or failures in these relationships, as highlighted in the risks, could disproportionately affect a company with limited internal manufacturing capabilities.
• The challenges in patient enrollment and regulatory discussions for the EC-042 trial, particularly concerning the evolving treatment landscape and FDA feedback on trial design, reflect broader industry trends where regulatory agencies are increasingly scrutinizing trial designs in rapidly advancing therapeutic areas.

Corporate Governance

Legal Proceedings

• Subject to potential litigation and damages by competitors under the CREATES Act, with three such requests received in June 2025, claiming insufficient quantities of approved products for generic/biosimilar testing.
• Discussion of ongoing litigation challenging the FDA's approval of mifepristone, which could potentially delay, undermine, or subject to protracted litigation the company's ability to develop new drug product candidates and maintain approval of existing drug products.
• Discussion of lawsuits filed against HHS and CMS challenging the IRA's Drug Price Negotiation Program, which could impact the prices the company obtains for its products.
• Faces inherent risk of product liability exposure related to commercialization of XPOVIO and testing of product candidates, potentially leading to lawsuits, substantial liabilities, and commercialization limits.
• Risk of warnings or enforcement action for off-label marketing if communications about approved products exceed approved indications.
• Exposure to criminal sanctions, civil penalties, contractual damages, and reputational harm for non-compliance with applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations.
• Risk of penalties and sanctions for non-compliance with complex reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental drug pricing programs.
• Subject to significant fines and penalties, and other consequences, for failure to comply with stringent privacy laws, information security laws, regulations, policies, and contractual obligations related to data privacy and security.
• Exposed to risks of fraud or other misconduct by employees, independent contractors, consultants, collaborators, and vendors, including non-compliance with regulatory standards and insider trading, which could cause significant liability.
• Could become subject to fines or penalties or incur costs for failure to comply with environmental, health and safety laws and regulations.
• Subject to laws and regulations governing international operations (e.g., FCPA, UK Bribery Act) that may preclude development, manufacturing, and selling certain products outside the U.S. and require costly compliance programs.
• Risk of securities class action litigation following a decline or periods of volatility in the market price of its securities.

Related Party Transactions

• The Credit Agreement was entered into with certain existing holders of the 2025 Notes and certain entities managed by HealthCare Royalty Management, LLC (HCRx), which was subsequently assigned to an affiliate of KKR & Co. Inc. (KKR).
• The 2029 Notes were issued to certain 2025 Note holders in exchange for 2025 Notes and to HCRx in exchange for a reduction in the deferred royalty obligation.
• The Amended Revenue Interest Agreement was with HCRx, subsequently assigned to KKR.
• Warrants were issued to HCRx.
• Clinical investigators for clinical trials may serve as scientific advisors or consultants and receive compensation, with reporting requirements to regulatory authorities under certain circumstances.

Stakeholder Impact

• Shareholders face significant risk of dilution from potential equity offerings and exercise of warrants. There is a potential for total loss of investment if the company pursues dissolution and liquidation. Stock price volatility and potential delisting from Nasdaq could adversely affect liquidity and ability to sell shares.
• Employees are impacted by workforce reductions (approximately 20% on July 11, 2025, following previous reductions), which may decrease morale, productivity, and lead to increased turnover. Job security is at risk due to the going concern doubt and potential strategic alternatives.
• Customers (Patients/Healthcare Providers) may experience limitations on future treatment options due to potential delays or curtailment of R&D programs. Unacceptable side effects or product recalls could impact patient trust and access to XPOVIO. Changes in reimbursement policies could affect affordability and access.
• Suppliers and Creditors face risks due to the company's substantial debt ($356.7 million) and the disclosed going concern doubt. There is a potential for acceleration of debt payments or foreclosure on pledged collateral if covenants are violated. Suppliers face risk of delayed or non-payment if financial condition deteriorates.
• Partners (Menarini, Antengene, KKR) are affected by the company's financial instability and potential strategic alternatives, which could impact the viability and terms of existing collaborations. KKR, as a significant creditor and royalty holder, is directly impacted by the company's financial health and ability to meet obligations.

Next Steps

• Obtain additional funding through equity offerings, debt financings and refinancings, collaborations, strategic alliances, and/or licensing arrangements.
• Evaluate potential financing transactions and strategic alternatives, including a potential merger or sale of the company, in or out of court restructurings, repurchases, redemptions, exchanges or other refinancings of existing debt.
• Close new patient screening in the Phase 3 myelofibrosis trial in August 2025.
• Report top-line data from the Phase 3 myelofibrosis trial in March 2026.
• Continue to invest in myelofibrosis and endometrial cancer Phase 3 clinical trials.
• File Amendment No. 4 to the license agreement with Berlin-Chemie AG as an exhibit to the Quarterly Report on Form 10-Q for the three months ended September 30, 2025.
• Continue to educate physicians, other healthcare providers, and patients about XPOVIO's clinical profile and unique mechanism of action.
• Seek additional approvals for the use of selinexor as a single agent or in combination with other oncology therapies.
• Comply with post-marketing commitments for XPOVIO's accelerated approvals.
• Monitor and navigate FDA regulations, guidance, and policies, along with recently enacted legislation, to ensure compliance with restrictions governing product promotion.
• Address the implications of recent changes to data privacy regulations and ensure compliance with evolving data protection rules.
• Continue to comply with the terms of the CREATES Act regarding providing drug product for generic/biosimilar testing.

Key Dates

Recommendation

The company explicitly states 'substantial doubt regarding our ability to continue as a going concern within one year' and projects its cash runway only into October 2025, primarily due to a $24.5 million debt maturity. This severe liquidity crisis, coupled with significant and widening net losses, declining total revenue, and substantial existing indebtedness, presents an extremely high risk profile. While management is exploring strategic alternatives, there is no assurance of success, and a potential dissolution and liquidation could result in a total loss for stockholders. Despite some positive operational cost reductions, the fundamental financial viability is in question, making the stock a strong sell for investors.

Keywords

Karyopharm, Therapeutics, XPOVIO, Selinexor, Cancer, Oncology, Myeloma, Myelofibrosis, Endometrial Cancer, DLBCL, Biotechnology, Pharmaceutical, SEC Filing, 10-Q, Financials, Clinical Trials, Drug Development, Going Concern, Debt, Liquidity, Nasdaq, Reverse Stock Split, Corporate Governance, Risk Management